Skip to content
Screener

TriSalus Life Sciences, Inc. TLSI Q1 2025 Annual earnings

Reported May 15, 2025 · Before market open

Revenue$9.2MBeat by $72.1K
EPS-$0.33Miss by $0.13
Revenue estimate$9.1M
EPS estimate-$0.20

Next report

Nov 12, 2026 (in a month)
Revenue estimate$14.0M
EPS estimate-$0.14

Financials

Q1 2025

Income statement

See full
Revenue$9.2M+42.0%
Gross profit$7.7M+39.8%
Operating income-$7.3M+37.2%
Net income-$10.4M+21.4%
EPS (diluted)-$0.39+35.0%

Balance sheet

See full
Cash & equivalents$13.4M+209%
Total debt$31.7M—
Total equity-$34.4M+4.6%
Total assets$28.6M+60.0%

Cash flow

See full
Operating cash flow-$4.5M+58.6%
CapEx$754.0K+1,042%
Free cash flow-$5.3M+52.0%

Valuation & ratios

Valuation

as of 03/31/25
See full
Market cap$172.66M-24.1%
Enterprise value$191.01M—
P/S5.4×-5.0×

Profitability

See full
Gross margin85.6%-1.1pp
Operating margin-99%-37.6pp
Net margin-84.7%-35.2pp
FCF margin-110.5%-38.2pp

Returns & leverage

See full
Current ratio2.1×+1.2×

FAQ

When did TriSalus Life Sciences, Inc. report Q1 2025 earnings?
TriSalus Life Sciences, Inc. (TLSI) reported Q1 2025 earnings on May 15, 2025 before market open.
What were TriSalus Life Sciences, Inc.'s Q1 2025 revenue and EPS?
TriSalus Life Sciences, Inc. reported revenue of $9.2M and eps of $-0.33 for Q1 2025.
Did TriSalus Life Sciences, Inc. beat estimates in Q1 2025?
Revenue beat the consensus estimate of $9.1M by $72.1K. EPS missed the consensus estimate of $-0.20 by $0.13.
How did TriSalus Life Sciences, Inc.'s Q1 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 42.0% from $6.5M a year earlier and eps grew 38.9% from $-0.54.
Where can I find TriSalus Life Sciences, Inc.'s Q1 2025 SEC filings?
You can read the 8-K earnings release (0001826667-25-000049) and the 10-K periodic report (0001826667-25-000030) directly on SEC EDGAR. The filing index links above go to sec.gov.